相关实验视频

Updated: Jan 13, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

NEAT1/miR-506-3p/STAT3轴促进皮膜黑色素瘤的进展,并代表了一个潜在的治疗点

Xiangyu Liu¹, Mengdi Zhang¹, Lijie Hao¹

¹Department of Ophthalmology, Second Hospital of Jilin University, Nanguan District, No.218 Ziqiang Street, Changchun, 130000, People's Republic of China.

Cancer cell international

|January 11, 2026

概括

这项研究揭示了NEAT1/miR-506-3p/STAT3通路驱动了皮膜黑色素瘤 (UM) 的进展. 针对这一轴提供了UM治疗的新策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学遗传学是一个

背景情况:

卵巢黑色素瘤 (UM) 是一种具有高转移潜力的眼内癌症,缺乏有效的治疗方法.
长非编码RNAs (lncRNAs) 和microRNAs (miRNAs) 都与癌症的发展有关.
lncRNA-NEAT1因其促进瘤生长的作用而得到认可.

研究的目的:

研究UM中NEAT1,miR-506-3p和STAT3的表达和功能.
为了阐明UM病变的调节轴NEAT1/miR-506-3p/STAT3.
探索这一轴作为UM的潜在诊断和治疗目标.

主要方法:

在UM细胞与正常细胞中对NEAT1,miR-506-3p和STAT3表达的比较分析.
在体外实验中评估NEAT1和miR-506-3p操纵对UM细胞行为的影响.
生物信息分析和双露西法酶记者测定证实了分子相互作用.
救援实验以验证NEAT1/miR-506-3p/STAT3轴的有效性.

主要成果:

在UM细胞中观察到NEAT1,miR-506-3p和STAT3的异常表达.
NEAT1抑制或miR-506-3p过度表达抑制了UM细胞的增殖,迁移和入侵.
证实了NEAT1/miR-506-3p/STAT3的相互作用,miR-506-3p直接针对NEAT1并调节STAT3.
NEAT1/miR-506-3p/STAT3轴在UM细胞的生物行为中起着至关重要的作用.

结论:

NEAT1/miR-506-3p/STAT3轴是皮膜黑色素瘤进展的关键驱动因素.
这一途径代表了UM中新型诊断和治疗策略的有希望的目标.
了解这个轴向,可以让我们对UM背后的分子机制有新的见解.

关键词:

在CeRNA网络中,这是一个LncRNARNA.在 MiR-506-3pp 中使用.在NEAT1中,NEAT1是NEEAT1的类型.在STAT3中,我们可以使用STAT3.在Uveal黑色素瘤.

更多相关视频

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

相关概念视频

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

MAPK Signaling Cascades

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...